Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   43857   clinical trials with a EudraCT protocol, of which   7284   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     

    < Back to search results

    Print Download

    Summary
    EudraCT Number:2012-005736-29
    Sponsor's Protocol Code Number:178-CL-102
    National Competent Authority:Spain - AEMPS
    Clinical Trial Type:EEA CTA
    Trial Status:Completed
    Date on which this record was first entered in the EudraCT database:2014-01-16
    Trial results View results
    Index
    A. PROTOCOL INFORMATION
    B. SPONSOR INFORMATION
    C. APPLICANT IDENTIFICATION
    D. IMP IDENTIFICATION
    D.8 INFORMATION ON PLACEBO
    E. GENERAL INFORMATION ON THE TRIAL
    F. POPULATION OF TRIAL SUBJECTS
    G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL
    N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED
    P. END OF TRIAL
    Expand All   Collapse All
    A. Protocol Information
    A.1Member State ConcernedSpain - AEMPS
    A.2EudraCT number2012-005736-29
    A.3Full title of the trial
    A Randomized, Double-Blind, Parallel-Group, Active-Controlled, Multi-center Study to Evaluate the Long-Term Safety and Efficacy of Combination of Solifenacin Succinate with Mirabegron Compared to Solifenacin Succinate and Mirabegron Monotherapy in Subjects with Overactive Bladder
    Estudio aleatorizado, doble ciego, de grupos paralelos, control activo y multicéntrico para la evaluación de la seguridad y la eficacia a largo plazo de la combinación de succinato de solifenacina con Mirabegron en comparación con monoterapias de succinato de solifenacina y de Mirabegron en sujetos con vejiga hiperactiva
    A.3.1Title of the trial for lay people, in easily understood, i.e. non-technical, language
    A study to assess the long-term efficacy and safety of two medicines, solifenacin succinate and mirabegron, taken together or separately, in patients with overactive bladder
    Estudio para evaluar la eficacia y la seguridad a largo plazo de dos medicamentos, succinato de solifenacina y mirabegron, tomados juntos o separadamente, en pacientes con vejiga hiperactiva
    A.4.1Sponsor's protocol code number178-CL-102
    A.5.4Other Identifiers
    Name:SYNERGY IINumber:Study Name
    A.7Trial is part of a Paediatric Investigation Plan No
    A.8EMA Decision number of Paediatric Investigation Plan
    B. Sponsor Information
    B.Sponsor: 1
    B.1.1Name of SponsorAstellas Pharma Europe B.V.
    B.1.3.4CountryNetherlands
    B.3.1 and B.3.2Status of the sponsorCommercial
    B.4 Source(s) of Monetary or Material Support for the clinical trial:
    B.4.1Name of organisation providing supportAstellas Pharma Europe B.V.
    B.4.2CountryNetherlands
    B.5 Contact point designated by the sponsor for further information on the trial
    B.5.1Name of organisationAstellas Pharma Europe B.V.
    B.5.2Functional name of contact pointService Desk - Gobal Clinical Dev't
    B.5.3 Address:
    B.5.3.1Street AddressSylviusweg 62
    B.5.3.2Town/ cityLeiden
    B.5.3.3Post code2300 AH
    B.5.3.4CountryNetherlands
    B.5.6E-mailcontact@nl.astellas.com
    D. IMP Identification
    D.IMP: 1
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation Yes
    D.2.1.1.1Trade name Vesicare
    D.2.1.1.2Name of the Marketing Authorisation holderAstellas Pharma Europe B.V.
    D.2.1.2Country which granted the Marketing AuthorisationNetherlands
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product namesolifenacin succinate
    D.3.4Pharmaceutical form Film-coated tablet
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPOral use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNsolifenacin succinate
    D.3.9.1CAS number 242478-38-2
    D.3.9.2Current sponsor codeYM905
    D.3.9.3Other descriptive nameSOLIFENACIN SUCCINATE
    D.3.9.4EV Substance CodeSUB21028
    D.3.10 Strength
    D.3.10.1Concentration unit mg milligram(s)
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number5
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product No
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.IMP: 2
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation Yes
    D.2.1.1.1Trade name Betmiga
    D.2.1.1.2Name of the Marketing Authorisation holderAstellas Pharma Europe B.V.
    D.2.1.2Country which granted the Marketing AuthorisationEuropean Union
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product nameMirabegron
    D.3.2Product code YM178
    D.3.4Pharmaceutical form Prolonged-release tablet
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPOral use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNmirabegron
    D.3.9.1CAS number 223673-61-8
    D.3.9.3Other descriptive nameMIRABEGRON
    D.3.9.4EV Substance CodeSUB32690
    D.3.10 Strength
    D.3.10.1Concentration unit mg milligram(s)
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number50
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product No
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.8 Information on Placebo
    D.8 Placebo: 1
    D.8.1Is a Placebo used in this Trial?Yes
    D.8.3Pharmaceutical form of the placeboFilm-coated tablet
    D.8.4Route of administration of the placeboOral use
    D.8 Placebo: 2
    D.8.1Is a Placebo used in this Trial?Yes
    D.8.3Pharmaceutical form of the placeboFilm-coated tablet
    D.8.4Route of administration of the placeboOral use
    E. General Information on the Trial
    E.1 Medical condition or disease under investigation
    E.1.1Medical condition(s) being investigated
    Overactive Bladder
    Vejiga hiperactiva
    E.1.1.1Medical condition in easily understood language
    Overactive Bladder
    Vejiga hiperactiva
    E.1.1.2Therapeutic area Body processes [G] - Physical Phenomena [G01]
    MedDRA Classification
    E.1.2 Medical condition or disease under investigation
    E.1.2Version 16.1
    E.1.2Level LLT
    E.1.2Classification code 10059617
    E.1.2Term Overactive bladder
    E.1.2System Organ Class 100000004857
    E.1.3Condition being studied is a rare disease No
    E.2 Objective of the trial
    E.2.1Main objective of the trial
    To evaluate the safety and tolerability of long-term combination treatment of solifenacin (5 mg) with mirabegron (50 mg) compared to solifenacin and mirabegron monotherapy in subjects with overactive bladder (OAB)
    Evaluar la seguridad y la tolerabilidad del tratamiento combinado a largo plazo con solifenacina (5 mg) y Mirabegron (50 mg) en comparación con monoterapias de solifenacina y Mirabegron en sujetos con vejoga hiperactiva
    E.2.2Secondary objectives of the trial
    To evaluate efficacy of long-term combination treatment with solifenacin and mirabegron

    To evaluate Patient Reported Outcomes (PRO) during long-term combination treatment with solifenacin and mirabegron
    Evaluar la eficacia del tratamiento combinado a largo plazo con solifenacina y Mirabegron

    Evaluar los resultados percibidos por el paciente (RPP) durante el tratamiento combinado a largo plazo con solifenacina y Mirabegron
    E.2.3Trial contains a sub-study No
    E.3Principal inclusion criteria
    ? Subject is male or female and at least 18 years of age;
    ? Subject is willing and able to complete the micturition diary and questionnaires correctly and able to measure his/her vital signs at home at stipulated time points, using the device provided by the study personnel, and to adequately record the readings;
    ? Subject has symptoms of ?wet? OAB for at least three months
    ? El sujeto es hombre o mujer con una edad mínima de 18 años.
    ? El sujeto está dispuesto y es capaz de rellenar correctamente el diario de micciones y los cuestionarios, y es capaz de tomar sus constantes vitales en su hogar en momentos estipulados, mediante el dispositivo proporcionado por el personal del estudio, y registrar de forma adecuada los valores observados.
    ? El sujeto presenta síntomas de VH ?húmeda? durante al menos 3 meses.
    E.4Principal exclusion criteria
    ? Subject has neurological cause for detrusor overactivity (e.g.
    neurogenic bladder, diabetic neuropathy or systemic or central
    neurological disease such as multiple sclerosis and Parkinson's disease).
    ? Subject has chronic inflammation such as bladder pain syndrome /
    interstitial cystitis, symptomatic bladder stones or any previous or
    current radiation cystitis.
    ? Subject has moderate to severe hepatic impairment
    ? Subject has severe renal impairment
    ? Subject has a clinically significant abnormal ECG
    ? Subject has a concurrent malignancy or history of cancer (except
    noninvasive skin cancer) within the last 5 years prior to screening.
    ? Subject has a QTcF interval > 450 ms for males or > 470 ms for
    females or is at risk of QT prolongation (e.g., family history of long QT
    syndrome, hypokalaemia).
    ? Subject has severe hypertension, which is defined as a sitting
    average systolic blood pressure ? 180 mmHg and/or average diastolic
    blood pressure ? 110 mmHg.
    ? In the opinion of the investigator the subject has clinically significant bladder outflow obstruction at risk of urinary retention;
    ? Subject has significant PVR volume (> 150 mL);
    ? Subject has significant stress incontinence or mixed stress/urgency incontinence where stress is the predominant factor as determined by the investigator;
    ? Subject has an indwelling catheter or practices intermittent self-catheterization;
    ? Subject has evidence of urinary tract infection (UTI), chronic inflammation such as interstitial cystitis, bladder stones, previous pelvic radiation therapy or previous or current malignant disease of the pelvic organs;
    ? Subject has had intravesical treatment in the past 12 months with e.g., botulinum toxin, resiniferatoxin, capsaicin;
    - Hay una causa neurológica para la hiperactividad del detrusor del paciente (p. ej., vejiga neurogénica, neuropatía diabética o sistémica o enfermedad del sistema neurológico central, como esclerosis múltiple y enfermedad de Parkinson).
    - El sujeto tiene inflamación crónica como síndrome de dolor vesical o cistitis intersticial, cálculos vesicales sintomáticos o cualquier cistitis por radiación previa o presente.
    - El sujeto sufre disfunción hepática entre moderada y grave.
    - El sujeto sufre de disfunción renal grave.
    - El sujeto tiene un ECG con una anomalía clínicamente significativa.
    - El sujeto padece una enfermedad maligna o posee historia de cáncer (excepto cáncer de piel no invasivo) en los 5 años previos a la selección.
    - El sujeto tiene un intervalo QTcF > 450 ms si es hombre o > 470 ms si es mujer, o sufre riesgo de prolongación del QT (p. ej., antecedentes familiares de síndrome del QT largo, hipopotasemia).
    - El sujeto sufre de hipertensión grave, definida como una tensión arterial sistólica media ? 180 mmHg y/o una tensión arterial diastólica media ?110 mmHg en posición sentada.
    - En opinión del investigador, el sujeto sufre una obstrucción del flujo urinario clínicamente significativa, con riesgo de retención urinaria.
    - El sujeto tiene un VRP significativo (>150 ml).
    - El sujeto padece incontinencia de esfuerzo o una combinación de incontinencia de esfuerzo y de urgencia combinadas, con el esfuerzo como factor predominante según el criterio del investigador.
    - El sujeto lleva una sonda urinaria permanente o se somete autocateterismo intermitente.
    - El sujeto muestra signos de infección del tracto urinario (ITU), inflamación crónica como cistitis intersticial, cálculos vesicales , cistitis por radiación previa o padece una enfermedad pélvica maligna.
    - El sujeto ha recibido tratamiento intravesical en los últimos 12 meses, por ejemplo, con toxina botulínica, resiniferatoxina, capsaicina
    E.5 End points
    E.5.1Primary end point(s)
    ? Incidence and severity of treatment emergent adverse events (TEAEs)

    Primary Efficacy Variables
    ? Change from baseline in mean number of incontinence episodes per 24 hours at EoT
    ? Change from baseline in mean number of micturitions per 24 hours at EoT
    - Incidencia y gravedad de los acontecimientos adversos aparecidos durante el tratamiento (AAAT)

    Variables de eficacia principales
    ? Cambio respecto a la situación basal en la media de episodios de incontinencia por periodo de 24 horas en el FdT
    ? Cambio respecto a la situación basal en la media de micciones por periodo de 24 horas en el FdT
    E.5.1.1Timepoint(s) of evaluation of this end point
    EoT
    FdT (fin de tratamiento)
    E.5.2Secondary end point(s)
    ? Vital signs
    ? Laboratory test
    ? ECG parameters
    ? PVR
    ? Constantes vitales:
    ? Pruebas de laboratorio:
    ? Parámetros del ECG
    ? VRP
    E.5.2.1Timepoint(s) of evaluation of this end point
    EoT
    FdT (fin de tratamiento)
    E.6 and E.7 Scope of the trial
    E.6Scope of the trial
    E.6.1Diagnosis No
    E.6.2Prophylaxis No
    E.6.3Therapy Yes
    E.6.4Safety Yes
    E.6.5Efficacy Yes
    E.6.6Pharmacokinetic No
    E.6.7Pharmacodynamic No
    E.6.8Bioequivalence No
    E.6.9Dose response No
    E.6.10Pharmacogenetic No
    E.6.11Pharmacogenomic No
    E.6.12Pharmacoeconomic No
    E.6.13Others No
    E.7Trial type and phase
    E.7.1Human pharmacology (Phase I) No
    E.7.1.1First administration to humans No
    E.7.1.2Bioequivalence study No
    E.7.1.3Other No
    E.7.1.3.1Other trial type description
    E.7.2Therapeutic exploratory (Phase II) No
    E.7.3Therapeutic confirmatory (Phase III) Yes
    E.7.4Therapeutic use (Phase IV) No
    E.8 Design of the trial
    E.8.1Controlled Yes
    E.8.1.1Randomised Yes
    E.8.1.2Open No
    E.8.1.3Single blind No
    E.8.1.4Double blind Yes
    E.8.1.5Parallel group Yes
    E.8.1.6Cross over No
    E.8.1.7Other No
    E.8.2 Comparator of controlled trial
    E.8.2.1Other medicinal product(s) Yes
    E.8.2.2Placebo No
    E.8.2.3Other No
    E.8.2.4Number of treatment arms in the trial3
    E.8.3 The trial involves single site in the Member State concerned No
    E.8.4 The trial involves multiple sites in the Member State concerned Yes
    E.8.4.1Number of sites anticipated in Member State concerned8
    E.8.5The trial involves multiple Member States Yes
    E.8.5.1Number of sites anticipated in the EEA188
    E.8.6 Trial involving sites outside the EEA
    E.8.6.1Trial being conducted both within and outside the EEA Yes
    E.8.6.2Trial being conducted completely outside of the EEA No
    E.8.6.3If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned
    Belgium
    Bulgaria
    Canada
    China
    Denmark
    France
    Greece
    Italy
    Netherlands
    New Zealand
    Norway
    Romania
    Slovakia
    Sweden
    Argentina
    Australia
    Brazil
    Chile
    Colombia
    Czech Republic
    Estonia
    Finland
    Germany
    Hong Kong
    Hungary
    India
    Indonesia
    Korea, Republic of
    Latvia
    Lithuania
    Malaysia
    Spain
    Thailand
    Mexico
    Peru
    Philippines
    Poland
    Russian Federation
    Singapore
    Slovenia
    South Africa
    Taiwan
    Turkey
    Ukraine
    United Kingdom
    United States
    E.8.7Trial has a data monitoring committee No
    E.8.8 Definition of the end of the trial and justification where it is not the last visit of the last subject undergoing the trial
    LVLS
    Última visita del último paciente
    E.8.9 Initial estimate of the duration of the trial
    E.8.9.1In the Member State concerned years2
    E.8.9.1In the Member State concerned months1
    E.8.9.1In the Member State concerned days0
    E.8.9.2In all countries concerned by the trial years2
    E.8.9.2In all countries concerned by the trial months1
    E.8.9.2In all countries concerned by the trial days0
    F. Population of Trial Subjects
    F.1 Age Range
    F.1.1Trial has subjects under 18 No
    F.1.1.1In Utero No
    F.1.1.2Preterm newborn infants (up to gestational age < 37 weeks) No
    F.1.1.3Newborns (0-27 days) No
    F.1.1.4Infants and toddlers (28 days-23 months) No
    F.1.1.5Children (2-11years) No
    F.1.1.6Adolescents (12-17 years) No
    F.1.2Adults (18-64 years) Yes
    F.1.2.1Number of subjects for this age range: 1728
    F.1.3Elderly (>=65 years) Yes
    F.1.3.1Number of subjects for this age range: 672
    F.2 Gender
    F.2.1Female Yes
    F.2.2Male Yes
    F.3 Group of trial subjects
    F.3.1Healthy volunteers No
    F.3.2Patients Yes
    F.3.3Specific vulnerable populations Yes
    F.3.3.1Women of childbearing potential not using contraception No
    F.3.3.2Women of child-bearing potential using contraception Yes
    F.3.3.3Pregnant women No
    F.3.3.4Nursing women No
    F.3.3.5Emergency situation No
    F.3.3.6Subjects incapable of giving consent personally No
    F.3.3.7Others No
    F.4 Planned number of subjects to be included
    F.4.1In the member state84
    F.4.2 For a multinational trial
    F.4.2.1In the EEA 600
    F.4.2.2In the whole clinical trial 1800
    F.5 Plans for treatment or care after the subject has ended the participation in the trial (if it is different from the expected normal treatment of that condition)
    None
    Ninguno
    G. Investigator Networks to be involved in the Trial
    N. Review by the Competent Authority or Ethics Committee in the country concerned
    N.Competent Authority Decision Authorised
    N.Date of Competent Authority Decision2014-01-28
    N.Ethics Committee Opinion of the trial applicationFavourable
    N.Ethics Committee Opinion: Reason(s) for unfavourable opinion
    N.Date of Ethics Committee Opinion2014-01-15
    P. End of Trial
    P.End of Trial StatusCompleted
    P.Date of the global end of the trial2016-09-08
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Tue Apr 23 15:52:14 CEST 2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA